IV Sodium Ferric Gluconate Complex in Patients Undergoing TAVI

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

Also called NCT04797832

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04797832
Other papers using this trial's data
  • The effect of intravenous sodium ferric gluconate complex (Ferrlecit) on outcomes of patients undergoing transcatheter aortic valve implantation: a prospective randomized controlled trial Journal of cardiovascular medicine (Hagerstown, Md.), 2026-05-01 DOI, PubMed 41870899

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Israel (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04797832. Randomized; single masking; primary purpose treatment. Start 2020-10-18 (actual); primary completion 2024-10-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
IV Sodium Ferric Gluconate Complex in Patients Undergoing TAVI
Condition
Iron Deficiency Anemia Due to Blood Loss
Condition
Aortic Stenosis
Intervention (Drug)
IV Sodium Ferric Gluconate Complex
Lead sponsor
Rambam Health Care Campus (class: other)

Record details

Record id
cardio:ct-nct04797832
Content hash
863d3779dacaa1c992d518920fa47002d8e4da8f18a162558d7439938751da50